Celltrion to launch Temixys double combination once-daily tablet for HIV treatment in US

This article was originally published here

Celltrion anticipates Temixys to be available in the next coming weeks. Temixys (lamivudine and tenofovir disoproxil fumarate) 300mg/300mg is a once-daily combination of two nucleoside reverse transcriptase inhibitors,

The post Celltrion to launch Temixys double combination once-daily tablet for HIV treatment in US appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply